Northern Trust’s AN2 Therapeutics ANTX Stock Holding History
Bought
Maintained
Sold
Other funds holding ANTX
ACA
Northern Trust's ANTX Position: Q3 2026 in Review
Northern Trust reduced its AN2 Therapeutics (ANTX) stake by 2.3% in Q3 2026, selling an estimated $26.2K and leaving 209,978 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3368.
Northern Trust first reported a position in ANTX in Q2 2022 and has held it in 17 quarters since. 85 funds tracked by Wall St. Rank hold ANTX as of Q3 2026.
- Northern Trust held 209,978 shares of AN2 Therapeutics worth $1.12M as of Q3 2026.
- Northern Trust sold 4,943 AN2 Therapeutics shares in Q3 2026, an estimated $26.2K.
- AN2 Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q3 2026, its #3368 holding.
- Northern Trust first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 17 quarters since.
- 85 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2026.
Based on Northern Trust's 13F filing for Q3 2026, filed 16 Nov 2026.